Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome

Journal of ECT

Volumn 21, Issue 2, 2005, Pages 125-127

  Ozer, Feriha ^a,d   Meral, Hasan ^a   Aydin, Betul ^a   Hanoglu, Lutfu ^b   Aydemir, Tuba ^a   Oral, Timucin ^c  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Bakirkoy Neurology Center   (Turkey)

^c Bakirkoy State Hospital   (Turkey)

^d NONE   (Turkey)

Author keywords

Depression; Drug induced psychosis; Electroconvulsive therapy; Neuroleptic malignant syndrome; Parkinson's disease

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CITALOPRAM; CLOZAPINE; LEVODOPA; QUETIAPINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; IDIOPATHIC DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; PARANOID PSYCHOSIS; PARKINSON DISEASE; PSYCHOSIS;

ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; LEVODOPA; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 20444372682     PISSN: 10950680     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yct.0000159325.08303.45     Document Type: Article

References (37)

1. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115-138.
2. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. J Neurol. 2001;248(Suppl 3):28-31.
3. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 1998;10:187-193.
4. Burn DJ. Depression in Parkinson's disease. Eur J Neurol. 2002;9(Suppl 1):44-54.
5. Friedman JH. The management of the levodopa psychosis. Clin Neuropharmacol. 1991;14:283-295.
6. Wengel SP, Burke WJ, Pfeiffer RF, et al. Maintenance electroconvulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry. 1998;6:263-269.
7. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to L-dopa withdrawal. JAMA. 1985;254:2792-2795.
8. Sechi GP, Tanda F, Mutani R. Fatal hyperpraxia after withdrawal of levodopa. Neurology. 1984;34:249-251.
9. Casey DA. Electroconvulsive therapy in the neuroleptic malignant syndrome. Convuls Ther. 1987;3:278-283.
10. Addonizio G, Susman VL. ECT as a treatment for patients with symptoms of neuroleptic malignant syndrome. J Clin Psychiatry. 1987;48:102-105.
11. Nisijima K, Ishiguro T. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report five cases. J ECT. 1999;15:158-163.
12. Factor SA, Molho ES, Brown DL. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7:304-307.
13. Hoflich G, Burghof KW, Kasper S, et al. Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychosis with Parkinson's disease. Nervenarzt. 1994;65:202-205.
14. Faber R, Trimble MR. Electroconvulsive therapy in Parkinson's disease and other movement disorders. Mov Disord. 1991;6:293-303.
15. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci. 1988;15:32-34.
16. Friedman J, Gordon N. Electroconvulsive therapy in Parkinson's disease: A report on five cases. Convuls Ther. 1992;8:204-210.
17. Fahn S, Elton RL, and Members of the UPDRS Development Committee Unified Parkinson's disease rating scale. In Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson's Disease II. New York: Macmillan; 1987:153-163.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
19. Bertorini TE. Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin. 1997;15:649-671.
20. Prudic J, Olfson M, Marcus SC, et al. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55:301-312.
21. Fink M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry. 1996;39:1-4.
22. Caroff SN, Mann SC, Keck PE. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 1998;44:378-381.
23. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33:650-659.
24. Stern MB. Electroconvulsive therapy in untreated Parkinson's disease. Mov Disord. 1991;6:265.
25. Zervas IM, Fink M. ECT for refractory Parkinson's disease. Convuls Ther. 1991;7:222-223.
26. Fall PA, Ekman R, Granerus AK, et al. ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect. 1995;10:129-140.
27. Pridmore S, Yeo PT, Pasha MI. Electroconvulsive therapy for the physical signs of Parkinson's disease without depressive disorders. J Neurol Neurosurg Psychiatry. 1995;58:641-642.
28. Aarsland D, Larsen JP, Waage O, et al. Maintenance electroconvulsive therapy for Parkinson's disease. Convuls Ther. 1997;13:274-277.
29. Fall PA, Granerus AK. Maintenance ECT in Parkinson's disease. J Neural Transm. 1999;106:737-741.
30. Kellner CH, Beale MD, Pritchett JT, et al. Electroconvulsive therapy and Parkinson's disease: the case for further study. Psychopharmacol Bull. 1994;30:495-500.
31. Bolwig TG, Hertz MM, Paulson OB, et al. The permeability of the blood-brain barrier during electrically induced seizures in man. Eur J Clin Invest. 1977;7:87-93.
32. Kapur S, Mann JJ. Antidepressant action and the neurobiologic effects of ECT: human studies. In: Cofey CE, ed. The Clinical Science of Electroconvulsive Therapy. Washington, DC: American Psychiatric Press; 1993:235-250.
33. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworts; 1987:166-230.
34. Lang AE, Lozano AM. Parkinson's disease. Second of the parts. N Engl J Med. 1998;339:1130-1143.
35. Figiel GS, Hassen MA, Zorumski C, et al. ECT-induced delirium in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1991;3:405-411.
36. Oh JJ, Rummans TA, O'Connor MK, et al. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness. Am J Psychiatry. 1992;149:271.
37. Nymeyer L, Grossberg GT. Delirium in a 75-year-old women receiving ECT and levodopa. Convuls Ther. 1997;13:114-116.